Mycophenolate mofetil in primary glomerulopathies

V. Sepe, C. Libetta, M. G. Giuliano, G. Adamo, A. Dal Canton

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Mycophenolate mofetil is an immunosuppressive agent that blocks purine biosynthesis, inhibits T and B-lymphocyte and mesangial proliferation. Mycophenolate mofetil is not nephrotoxic like calcineurin inhibitors and is widely used in solid-organ transplantation. Recently, mycophenolate mofetil has been introduced in the treatment of autoimmune diseases and primary glomerulopathies. This review analyzes the literature currently available on the treatment of primary glomerulopathies with mycophenolate mofetil. Encouraging results have been obtained in minimal change nephropathy where it may help to reduce the use of steroids in these patients who are often very young. The results obtained in medium and high risk patients with focal segmental glomerulonephritis and idiopathic membranous nephropathy were less encouraging. Conflicting results have been reported on IgA nephropathy in controlled trials. None of these studies attained level A evidence, meaning that randomized control trials of sufficient statistical significance are necessary to estimate the real effectiveness of mycophenolate mofetil in primary glomerulopathies.

Original languageEnglish
Pages (from-to)154-162
Number of pages9
JournalKidney International
Volume73
Issue number2
DOIs
Publication statusPublished - Jan 10 2008

Fingerprint

Mycophenolic Acid
Lipoid Nephrosis
Membranous Glomerulonephritis
Organ Transplantation
Immunosuppressive Agents
Glomerulonephritis
Immunoglobulin A
Autoimmune Diseases
B-Lymphocytes
Steroids
Therapeutics

Keywords

  • Focal segmental glomerulosclerosis
  • Idiopathic membranous nephropathy
  • IgA nephropathy
  • Minimal change nephropathy
  • Mycophenolate mofetil
  • Steroids

ASJC Scopus subject areas

  • Nephrology

Cite this

Mycophenolate mofetil in primary glomerulopathies. / Sepe, V.; Libetta, C.; Giuliano, M. G.; Adamo, G.; Dal Canton, A.

In: Kidney International, Vol. 73, No. 2, 10.01.2008, p. 154-162.

Research output: Contribution to journalArticle

Sepe, V. ; Libetta, C. ; Giuliano, M. G. ; Adamo, G. ; Dal Canton, A. / Mycophenolate mofetil in primary glomerulopathies. In: Kidney International. 2008 ; Vol. 73, No. 2. pp. 154-162.
@article{6089991f97774241b09793d5b2be39ae,
title = "Mycophenolate mofetil in primary glomerulopathies",
abstract = "Mycophenolate mofetil is an immunosuppressive agent that blocks purine biosynthesis, inhibits T and B-lymphocyte and mesangial proliferation. Mycophenolate mofetil is not nephrotoxic like calcineurin inhibitors and is widely used in solid-organ transplantation. Recently, mycophenolate mofetil has been introduced in the treatment of autoimmune diseases and primary glomerulopathies. This review analyzes the literature currently available on the treatment of primary glomerulopathies with mycophenolate mofetil. Encouraging results have been obtained in minimal change nephropathy where it may help to reduce the use of steroids in these patients who are often very young. The results obtained in medium and high risk patients with focal segmental glomerulonephritis and idiopathic membranous nephropathy were less encouraging. Conflicting results have been reported on IgA nephropathy in controlled trials. None of these studies attained level A evidence, meaning that randomized control trials of sufficient statistical significance are necessary to estimate the real effectiveness of mycophenolate mofetil in primary glomerulopathies.",
keywords = "Focal segmental glomerulosclerosis, Idiopathic membranous nephropathy, IgA nephropathy, Minimal change nephropathy, Mycophenolate mofetil, Steroids",
author = "V. Sepe and C. Libetta and Giuliano, {M. G.} and G. Adamo and {Dal Canton}, A.",
year = "2008",
month = "1",
day = "10",
doi = "10.1038/sj.ki.5002653",
language = "English",
volume = "73",
pages = "154--162",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Mycophenolate mofetil in primary glomerulopathies

AU - Sepe, V.

AU - Libetta, C.

AU - Giuliano, M. G.

AU - Adamo, G.

AU - Dal Canton, A.

PY - 2008/1/10

Y1 - 2008/1/10

N2 - Mycophenolate mofetil is an immunosuppressive agent that blocks purine biosynthesis, inhibits T and B-lymphocyte and mesangial proliferation. Mycophenolate mofetil is not nephrotoxic like calcineurin inhibitors and is widely used in solid-organ transplantation. Recently, mycophenolate mofetil has been introduced in the treatment of autoimmune diseases and primary glomerulopathies. This review analyzes the literature currently available on the treatment of primary glomerulopathies with mycophenolate mofetil. Encouraging results have been obtained in minimal change nephropathy where it may help to reduce the use of steroids in these patients who are often very young. The results obtained in medium and high risk patients with focal segmental glomerulonephritis and idiopathic membranous nephropathy were less encouraging. Conflicting results have been reported on IgA nephropathy in controlled trials. None of these studies attained level A evidence, meaning that randomized control trials of sufficient statistical significance are necessary to estimate the real effectiveness of mycophenolate mofetil in primary glomerulopathies.

AB - Mycophenolate mofetil is an immunosuppressive agent that blocks purine biosynthesis, inhibits T and B-lymphocyte and mesangial proliferation. Mycophenolate mofetil is not nephrotoxic like calcineurin inhibitors and is widely used in solid-organ transplantation. Recently, mycophenolate mofetil has been introduced in the treatment of autoimmune diseases and primary glomerulopathies. This review analyzes the literature currently available on the treatment of primary glomerulopathies with mycophenolate mofetil. Encouraging results have been obtained in minimal change nephropathy where it may help to reduce the use of steroids in these patients who are often very young. The results obtained in medium and high risk patients with focal segmental glomerulonephritis and idiopathic membranous nephropathy were less encouraging. Conflicting results have been reported on IgA nephropathy in controlled trials. None of these studies attained level A evidence, meaning that randomized control trials of sufficient statistical significance are necessary to estimate the real effectiveness of mycophenolate mofetil in primary glomerulopathies.

KW - Focal segmental glomerulosclerosis

KW - Idiopathic membranous nephropathy

KW - IgA nephropathy

KW - Minimal change nephropathy

KW - Mycophenolate mofetil

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=37549015225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549015225&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5002653

DO - 10.1038/sj.ki.5002653

M3 - Article

VL - 73

SP - 154

EP - 162

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -